PPA
BDTX icon

Parametric Portfolio Associates’s Black Diamond Therapeutics BDTX Stock Holding History

Parametric Portfolio Associates’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$249K Buy
90,052
+52,550
+140% +$192K ﹤0.01% 3355
2021
Q4 		$200K Sell
37,502
-29,256
-44% -$204K ﹤0.01% 3425
2021
Q3 		$565K Buy
66,758
+37,630
+129% +$372K ﹤0.01% 3045
2021
Q2 		$355K Buy
29,128
+17,837
+158% +$353K ﹤0.01% 3209
2021
Q1 		$274K Buy
+11,291
New +$305K ﹤0.01% 3751

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's BDTX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Black Diamond Therapeutics (BDTX) stake by 140% in Q1 2022, buying an estimated $192K and bringing the position to 90,052 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #3355.

Parametric Portfolio Associates first reported a position in BDTX in Q1 2021 and has held it in 5 quarters since. The position peaked at $565K in Q3 2021. 87 funds tracked by Wall St. Rank hold BDTX as of Q1 2022.

  • Parametric Portfolio Associates held 90,052 shares of Black Diamond Therapeutics worth $249K as of Q1 2022.
  • Parametric Portfolio Associates bought 52,550 Black Diamond Therapeutics shares in Q1 2022, an estimated $192K.
  • Black Diamond Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3355 holding.
  • Parametric Portfolio Associates first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • Parametric Portfolio Associates's Black Diamond Therapeutics position peaked at $565K in Q3 2021.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.